Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | F13A1 | P00488 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | TGM1 | P22735 | 1/20 | 0.41 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27183715 | 0.91 | MAPT (0.51) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 | |
| SCHEMBL17375422 | 0.89 | GPR119 (0.46) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 | |
| SCHEMBL20046277 | 0.87 | ALDH1A1 (0.47) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 | |
| SCHEMBL30432629 | 0.87 | ALDH1A1 (0.47) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 | |
| SCHEMBL23044923 | 0.86 | ALDH1A1 (0.46) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 | |
| SCHEMBL20231917 | 0.86 | LMNA (0.46) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 | |
| SCHEMBL20231041 | 0.84 | MAPT (0.45) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 | |
| SCHEMBL20231926 | 0.84 | ALDH1A1 (0.45) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 | |
| SCHEMBL20231040 | 0.84 | SUV39H2 (0.47) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 | |
| SCHEMBL4930294 | 0.84 | MAPT (0.51) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3160967-B1 | N-(IMIDAZO[1,2-A]PYRAZIN-6-YL)-BENZAMIDE COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN LA ROCHE (CH) | 2019-05-08 | — | — | EP | disclosed |
| US-9975900-B2 | Substituted imidazo[1,2-α]pyrazines for treating spinal muscular atrophy | HOFFMANN-LA ROCHE INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170197969-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. (US) | 2017-07-13 | — | — | US | disclosed |
| EP-3160967-A1 | IMIDAZO[1,2-A]PYRAZIN-1YL-BENZAMIDE COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. Hoffmann-La Roche AG (CH) | 2017-05-03 | — | — | EP | disclosed |
| WO-2015197503-A1 | IMIDAZO[1,2-A]PYRAZIN-1YL-BENZAMIDE COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197969-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, PYGM, GYS1 | MAPT 542/4885ALDH1A1 880/4885LMNA 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.